Q linea AB (QLINEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q linea AB (QLINEA) has a cash flow conversion efficiency ratio of -0.099x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-30.19 Million ≈ $-3.25 Million USD) by net assets (Skr304.55 Million ≈ $32.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Q linea AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Q linea AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Q linea AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Q linea AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q linea AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mural Oncology plc
NASDAQ:MURA
|
-0.335x |
|
MoneyHero Limited Class A Ordinary Shares
NASDAQ:MNY
|
-0.007x |
|
Fundamental Global Inc.
NASDAQ:FGNX
|
-0.010x |
|
Panstar Enterprise Co.Ltd
KQ:054300
|
-0.016x |
|
Hammer Metals Ltd
AU:HMX
|
-0.019x |
|
SJM Co Ltd
KO:123700
|
0.046x |
|
Corentec Co Ltd
KQ:104540
|
0.100x |
|
Nath Bio-Genes (India) Limited
NSE:NATHBIOGEN
|
-0.160x |
Annual Cash Flow Conversion Efficiency for Q linea AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Q linea AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Q linea AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr338.00 Million ≈ $36.37 Million |
Skr-162.12 Million ≈ $-17.45 Million |
-0.480x | -107.22% |
| 2024-12-31 | Skr-27.46 Million ≈ $-2.95 Million |
Skr-182.50 Million ≈ $-19.64 Million |
6.647x | +651.58% |
| 2023-12-31 | Skr189.64 Million ≈ $20.41 Million |
Skr-228.52 Million ≈ $-24.59 Million |
-1.205x | +22.36% |
| 2022-12-31 | Skr161.63 Million ≈ $17.39 Million |
Skr-250.86 Million ≈ $-27.00 Million |
-1.552x | -162.15% |
| 2021-12-31 | Skr430.79 Million ≈ $46.36 Million |
Skr-255.05 Million ≈ $-27.45 Million |
-0.592x | +5.14% |
| 2020-12-31 | Skr380.20 Million ≈ $40.92 Million |
Skr-237.31 Million ≈ $-25.54 Million |
-0.624x | -25.36% |
| 2019-12-31 | Skr340.94 Million ≈ $36.69 Million |
Skr-169.76 Million ≈ $-18.27 Million |
-0.498x | -108.34% |
| 2018-12-31 | Skr513.46 Million ≈ $55.26 Million |
Skr-122.71 Million ≈ $-13.21 Million |
-0.239x | +99.43% |
| 2017-12-31 | Skr1.51 Million ≈ $162.72K |
Skr-62.87 Million ≈ $-6.77 Million |
-41.577x | -565.28% |
| 2016-12-31 | Skr8.45 Million ≈ $909.79K |
Skr-52.83 Million ≈ $-5.69 Million |
-6.250x | -- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more